An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid.
The results of a multicenter, open-label observation study evaluating the use of tazarotene in 1393 patients being treated for plaque psoriasis have been reported recently. The analysis of data from a subset of 166 patients who were switched from calcipotriene therapy, with or without a topical corticosteroid, to receive tazarotene plus a corticosteroid is reported here. This subset of 166 patients showed substantial additional improvements in efficacy and patient satisfaction over and above those already achieved with calcipotriene +/- corticosteroid treatment. The mean scores for overall severity of plaque psoriasis, plaque elevation, scaling, pruritus, and overall discomfort were reduced by 35%, 41%, 44%, 45%, and 40%, respectively, compared with baseline levels at the time of switching therapy. The severity of each of these parameters was reduced from mild-to-moderate at baseline to trace-to-mild after a mean of 10 weeks' treatment with tazarotene plus a corticosteroid.
Tanghetti
E A
EA
Department of Dermatology, University of California at Davis, USA.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002648:Child; D003430:Cross-Sectional Studies; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D012176:Retinoids
D000893:Anti-Inflammatory Agents; D002117:Calcitriol; D003879:Dermatologic Agents; D005938:Glucocorticoids; D009539:Nicotinic Acids; C055085:calcipotriene; C086827:tazarotene; D012176:Retinoids